glp 1 drugs and alcohol consumption GLP-1 Weight Loss Alcohol: Why Ozempic Reduces Both How GLP-1 Can Help in

Given the narrative/scoping scope, no protocol registration was performed, and we did not pool effect estimates

The molecule and safety profile are identical

A 2025 SHRM article estimates a months supply to cost between $1,000 and $1,500

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

Note: These products alone are not intended to diagnose, treat, cure, or prevent any disease

Weigh the risks of side effects Despite reports of some serious side effects, Levy says these medications have a pretty solid safety record